AIDS Therapies

Hydroxyurea Increases Potency of Anti-HIV Drugs in Two Different Ways

Published in Cancer Weekly, September 18th, 1995

NCI researchers say they have solved the riddle of why the cancer drug hydroxyurea enhances some anti-HIV drugs more than others.

Several teams of researchers have found that hydroxyurea increases the potency of antiretroviral nucleoside analogs (Lori et al., Science, 1994;266:801-5; Malley et al., PNAS, 1994;91:11017-21; and Gao et al., Mol Pharmacol, 1994;46:767-72).

This enhancement, however, is far greater for didanosine (ddI, 2',3'-dideoxyinosine) than for zidovudine (AZT, 3'-azido-3'deoxythymidine) or zalcitabine (ddC, 2',3'-dideoxycytidine).

Hydroxyurea is used as a cancer therapy because it acts as an antimetabolite by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry